Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Actym Therapeutics, Inc.
United States
- Berkeley, CA
- 20/10/2023
- Series A
- $59,500,000
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
- Industry Biotechnology Research
- Website https://actymthera.com/
- LinkedIn https://www.linkedin.com/company/actym-therapeutics-inc/about/
Related People
Christopher ThanosCo Founder
United States -
Belvedere Tiburon, California
• Significant entrepreneurial and leadership experience in the biotechnology industry
• 30 years R&D experience
• Design, engineering, and production of cell therapies, ADC's, enzymes, and alternative scaffolds
• Comprehensive understanding of pipeline flow, from lead optimization to IND, to clinical POC
• Established skills in competitive intelligence, strategy, due diligence, portfolio management
• Inventor on multiple issued patents covering biotherapeutics
• First author publications in high impact factor journals such as Science, PNAS, JACS
• Effectively managed large teams
• Invited speaker, workshop leader, conference chair at several international meetings
CipherOwl | $15,000,000 | (Oct 24, 2025)
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
OneAM | $4,700,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)